AURKA and acute myeloid leukemia: For example, a PROTAC consisting of alisertib, a clinically used ATP-competitive inhibitor of AURKA [207], and thalidomide, which induces protein degradation via cereblon-containing ubiquitin ligase, results in proteolysis of AURKA and arrest of the cell cycle in MV4-11 human acute myeloid leukemia cells [5].